Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
08/2003
08/27/2003CN1438875A Method for making particles for use in a pharmaceutical composition
08/27/2003CN1438023A Chinese preporatory medicine for treating lung disease
08/27/2003CN1438008A Chinese medicine for treating pulmonary heart disease
08/27/2003CN1438007A Chinese medicine for treating obstructive lung disease
08/27/2003CN1437989A Method for preparing Gongjinle medicinal liquor for treating tracheitis
08/27/2003CN1437982A Medicinal composition for treating mycoplasma pneumonia and preparation method and quality-control method
08/27/2003CN1437980A Chinese-caterpillar-fungus lung-clearing capsule
08/27/2003CN1437960A Chinese medicine for treating chronic bronchitisÒÇütuberculosis and asthma
08/27/2003CN1437944A Technology for producing Dekuiluan lozenge
08/27/2003CN1437939A Method for induding andrographolide by cyclodextrin and medicinal preparation
08/27/2003CN1437935A Method for preparing medicine for relieving cough and reducing sputum
08/27/2003CN1119346C Benzothiadiaxoles and derivatives
08/27/2003CN1119344C Heterocyclic substed, pyrrolidine amide derivatives
08/27/2003CN1119340C Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
08/27/2003CN1119328C Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists
08/27/2003CN1119157C Cough and asthma relieving and phlegm eliminating capsule and its preparation
08/26/2003US6610847 Tyrosine kinase inhibitors; immunosuppressants
08/26/2003US6610745 Use of 2-hydroxy-4-trifluoromethyl-benzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-KS
08/26/2003US6610742 Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists
08/26/2003US6610737 Non-psychotropic cannabinoids
08/26/2003US6610717 Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease
08/26/2003US6610715 Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
08/26/2003US6610700 Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example
08/26/2003US6610697 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
08/26/2003US6610695 Prophylaxis or treatment of CSBP/RK/p38 kinase mediated disease
08/26/2003US6610690 Administering optically pure (S,S) enantiomer of reboxetine
08/26/2003US6610688 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
08/26/2003US6610685 Fused indole derivatives
08/26/2003US6610683 Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
08/26/2003US6610665 2-(purin-9-yl)-tetrahydrofuran-3, 4-diol derivatives
08/26/2003US6610624 Method for enhancing catalytic activity with supercritical fluids
08/26/2003US6610523 Human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating
08/26/2003US6610319 Immune response modifier compounds for treatment of TH2 mediated and related diseases
08/21/2003WO2003068968A2 Mutated gene coding for a lat protein and the biological applications thereof
08/21/2003WO2003068936A2 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
08/21/2003WO2003068817A1 Management of mucosal viscosity by tff monomer peptides
08/21/2003WO2003068813A2 Group b streptococcus antigen
08/21/2003WO2003068812A2 Immune-modulating peptide made of s. aureus enterotoxin b
08/21/2003WO2003068811A2 Cytotoxic t-cell epitopes from chlamydia
08/21/2003WO2003068803A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003WO2003068760A2 Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders
08/21/2003WO2003068759A1 Piperazine derivatives as anti-inflammatory agents
08/21/2003WO2003068750A1 Jnk inhibitor
08/21/2003WO2003068749A1 Vanilloid receptor modulators
08/21/2003WO2003068747A1 Nicotinamide derivates useful as p38 inhibitors
08/21/2003WO2003068746A1 Aryl ureas as kinase inhibitors
08/21/2003WO2003068744A1 Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
08/21/2003WO2003068743A1 Chemical compounds
08/21/2003WO2003068722A1 Carboxylic acid compounds for use as surfactants
08/21/2003WO2003068264A1 New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
08/21/2003WO2003068254A1 Glycosaminoglycan-dnase combination therapy
08/21/2003WO2003068245A1 Use of polyanhydroglucuronic acid comprising microdispersed oxidised cellulose as immunomodulator
08/21/2003WO2003068237A1 Beta-sheet mimetics and composition and methods relating thereto
08/21/2003WO2003068235A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068234A1 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
08/21/2003WO2003068233A1 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
08/21/2003WO2003068232A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068230A1 Substituted pyridinones as modulators of p38 map kinase
08/21/2003WO2003068228A1 Aryl ureas with angiogenesis inhibiting activity
08/21/2003WO2003068225A1 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)
08/21/2003WO2003068224A2 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
08/21/2003WO2003068219A1 Use of anethole dithiolethione in lung cancer chemoprevention
08/21/2003WO2003068202A1 Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
08/21/2003WO2003068188A1 Combination therapy for respiratory disorders
08/21/2003WO2003068187A1 Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
08/21/2003WO2003068171A2 Method and composition for treatment of inflammation and aids-associated neurological disorders
08/21/2003WO2003067991A1 Compositions and methods for treatment of microbial infections
08/21/2003WO2003055913A3 Secreted protein
08/21/2003WO2003027075A3 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
08/21/2003WO2003024474A3 Anti-inflammatory agent
08/21/2003WO2003018052A8 Moraxella (branhamella) catarrhalis polypeptides and corresponding dna fragments
08/21/2003WO2003007930A3 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
08/21/2003WO2002088664A3 Control of compactability through crystallization
08/21/2003WO2002085384A3 Lubricious coatings for substrates
08/21/2003WO2002068650A3 Modified and stabilized gdf propeptides and uses thereof
08/21/2003WO2002057452A3 Human proteins, polynucleotides encoding them and methods of using the same
08/21/2003WO2002046158A3 Piperidine/piperazine-type inhibitors of p38 kinase
08/21/2003WO2002044209A3 Cytonkine receptor zcytor19
08/21/2003WO2002036573A3 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
08/21/2003WO2002010392A9 Mammalian dna binding membrane-associated protein-encoding gene and uses
08/21/2003WO2001097753A3 Novel methods using pyridine derivatives
08/21/2003WO2001066190A3 Methods and devices for use in performing pulmonary procedures
08/21/2003US20030158413 A thiochromane-7-carboxamide derivatives as Rho kinase enzyme inhibitor; nontoxic, anticancer agents
08/21/2003US20030158409 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
08/21/2003US20030158399 Compositions and methods for the treatment and diagnosis of immune disorders
08/21/2003US20030158390 Protein; Escherichia culture product; genetic engineering; fusion
08/21/2003US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof
08/21/2003US20030158246 For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis.
08/21/2003US20030158242 Salt with a sugar substitute, especially saccharin, cyclamate or acesulfame.
08/21/2003US20030158238 Treating diseases such as cancer, inflammatory disorders, restenosis,
08/21/2003US20030158226 Treating or preventing emphysema, cancer and dermatological disorders
08/21/2003US20030158225 Novel compounds
08/21/2003US20030158219 N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
08/21/2003US20030158217 Succinate and malonate complexes treatment of abnormal cell growth, such as cancer, and overexpression of erbB2, and inducing cell death
08/21/2003US20030158197 Certain alkylene diamine-substituted heterocycles
08/21/2003US20030158192 Activating cytokine biosynthesis, viricides treating a viral disease, antitumor agents, immunomodulators
08/21/2003US20030158189 Non-steroidal antiinflammatory agents treating bone disorders, Crohn's disease, and inflammatory bowel disease, respiratory disorders such as chronic obstructive pulmonary disease, infections, autoimmune diseases
08/21/2003US20030158187 Genetic polymorphisms in the preprotachy kinin gene
08/21/2003US20030158178 Heterocyclic retinoid compounds
08/21/2003US20030158176 Quaternary ammonium compounds
1 ... 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 ... 878